Three-Drug Combination for Status Epilepticus Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for status epilepticus, particularly those induced by nerve agents, are ineffective in arresting both responsive and refractory cases, leading to high mortality rates and cognitive deficits, with existing protocols failing to differentiate between responsive and refractory cases promptly and lacking a favorable safety profile.
Innovation Solution
Administering a combination of halothane or flurane, an anti-seizure benzodiazepine, and a barbiturate anti-convulsant, such as isoflurane, diazepam, and phenobarbital, to effectively treat status epilepticus before it becomes refractory, using various administration methods including inhalation, injection, and transdermal absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (atropine and pralidoxime chloride) are used, then systemic effects of nerve agent are prevented, but status epilepticus is not arrested
Solution Approach 1:
The patent combines three drugs (halothane/flurane, benzodiazepine, and barbiturate) into a single treatment formulation that can be administered together. This combination approach allows simultaneous action on multiple mechanisms of seizure termination, improving reliability in arresting both responsive and refractory status epilepticus cases that cannot be achieved with single or dual agents alone.
Solution Approach 2:
The treatment uses a composite pharmacological approach combining volatile anesthetics (halothane/flurane), benzodiazepines, and barbiturates. This composite drug regimen creates synergistic effects that enhance the overall effectiveness in terminating status epilepticus, particularly in refractory cases where individual agents fail to provide sufficient control.
2Ease of operation
If benzodiazepines alone are administered, then responsive cases are treated, but refractory cases remain untreated (40% failure rate)
Solution Approach 1:
The patent merges benzodiazepines with volatile anesthetics (halothane/flurane) and barbiturates into a unified treatment protocol. This combination maintains the ease of administration while significantly improving reliability, as the synergistic action of multiple agents ensures effective treatment of both responsive and refractory cases, eliminating the 40% failure rate associated with benzodiazepines alone.
Solution Approach 2:
The patent changes the therapeutic parameters by introducing volatile anesthetics and barbiturates alongside benzodiazepines. This parameter expansion creates a multi-level treatment approach that can address both responsive and refractory mechanisms, improving the overall effectiveness without complicating the administration process.
3Reliability
If barbiturate/anesthetic coma is used for refractory cases, then ictal activity is abated, but ICU resources are saturated and mortality remains high
Solution Approach 1:
The patent applies preliminary action by administering the three-drug combination before status epilepticus progresses to refractory states. The volatile anesthetic component (halothane/flurane) provides rapid sedation and seizure termination at the onset, preventing the need for subsequent prolonged barbiturate coma and intensive care resource utilization, thereby reducing both resource requirements and mortality.
Solution Approach 2:
The patent rushes through the treatment process by using the rapid-acting volatile anesthetic (halothane/flurane) combined with benzodiazepines and barbiturates to quickly terminate seizures before they become refractory. This accelerated approach skips the prolonged intensive care phase required for traditional refractory case management, reducing ICU resource saturation and improving outcomes.
4Productivity
If standard treatment protocols are used, then initial seizure activity is addressed, but cognitive deficits and post-SE epilepsy increase
Solution Approach 1:
The patent applies preliminary action by treating status epilepticus at the outset with the three-drug combination before it progresses to refractory states. This early intervention prevents the neuronal damage and excitotoxicity that lead to cognitive deficits and post-SE epilepsy, while maintaining effective seizure control. The volatile anesthetic component provides rapid protection against seizure-induced injury.
Solution Approach 2:
The patent converts the potentially harmful effect of volatile anesthetics (which can cause respiratory depression and hemodynamic changes) into a beneficial seizure-terminating mechanism. By using halothane/flurane in controlled concentrations as part of the combination, the treatment achieves superior seizure control and neurological protection compared to standard protocols, transforming a risky agent into a therapeutic advantage.
Data Source
AI summary
A method for treating non-refractory status epilepticus includes administering together before onset of refractory status epilepticus, a therapeutically effective amount of a combination of halothane or a flurane, an anti-seizure benzodiazepine, and a barbiturate anti-convulsant. The flurane may selected from one or more of isoflurane, desflurane and sevoflurane. The anti-seizure benzodiazepine may be diazepam and the barbiturate anti-convulsant may be phenobarbital.